Danaher has seen its share price drift lower in recent years, which puts a fresh spotlight on a simple question for investors who care about fundamentals. Is the current US$220.36 price tag adequately supported by the cash the business can generate over time, based on a Discounted Cash Flow (DCF) view of intrinsic value?
For investors, the debate is whether the current market price for Danaher lines up with what its cash flows imply when run through a Discounted Cash Flow (DCF) lens.
For context on how Danaher's cash flow question compares with similar stories in the market, it can help to scan solid balance sheet and fundamentals stocks screener (24 results).
The Discounted Cash Flow (DCF) approach used here estimates the cash Danaher might return to shareholders and then discounts those projected cash flows back to today. The latest twelve month free cash flow is about $5.6b, and the model assumes this pool of cash increases over time rather than decreases, with projected free cash flow reaching higher levels into the early 2030s before transitioning to a slower pace.
Based on those assumptions, the DCF projections suggest Danaher's estimated intrinsic value is broadly in line with the current share price of $220.36. Because the single use bioreactors market is expected to expand and Danaher is a key supplier in that field, the market may already be factoring that opportunity into the price, which may help explain why the DCF outcome is close to where the shares trade today. Find out what Danaher could be worth using our Discounted Cash Flow (DCF) estimate.
Simply Wall St Narratives give you a structured way to connect Danaher's DCF puzzle with the expectations sitting behind it, spelling out which paths for revenue, margins and earnings would need to play out for the stock to be worth meaningfully more or less than today. Instead of stopping at a single output from a ratio or model, Narratives unpack the specific future that number relies on so you can watch over time whether reality tracks that script on the Community page.
One of the top narratives on Danaher: 15% undervalued
This Narrative is the analyst consensus Narrative on Simply Wall St, which compiles analysts' consensus price target and revenue and earnings forecasts, not one person's view.
"The main factor that has to go right is that biologics and bioprocessing capacity investment, AI linked life sciences demand, and advanced diagnostics growth translate into sustained core revenue expansion..."
Discover why this Narrative puts Danaher at 15% undervalued.
Cash flows and scenarios only tell part of the story, because who runs Danaher and how their rewards are structured can heavily influence the path those numbers take over time. See who runs Danaher and how they are paid.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com